ArticleWorld journal of surgical oncology2025
Therapeutic value of dissecting stations 1 and 4Sb lymph nodes during radical distal gastrectomy for lower- and middle-third gastric cancer.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe necessity of dissecting station 1 (right paracardial) and 4Sb (left gastroepiploic artery) lymph nodes (LNs) during radical distal gastrectomy for gastric cancer remains debated. This study investigated their therapeutic value for lower-third (LGC) and middle-third (MGC) gastric cancer.
methodsThis retrospective cohort study analyzed 897 patients undergoing radical distal gastrectomy (2013-2019). Metastasis rates, clinicopathological associations, multivariate analyses for risk factors and survival and therapeutic value index (TVI = metastasis frequency × 5-year survival of station-positive patients) for stations 1 and 4Sb were assessed, stratified by tumor location.
resultsFor LGC (n = 435), station 4Sb showed a 0.46% metastasis rate and a 0% TVI. In contrast, station 1 had a 5.06% metastasis rate and a TVI of 4.14%. Multivariate survival analysis for LGC revealed that after adjusting for T and N stage, station 1 metastasis was not an independent prognostic factor for overall survival (HR 1.60, 95% CI 0.95-2.71, p = 0.078). For MGC (n = 462), station 1 metastasis was an independent prognostic factor (HR 1.75, 95% CI 1.08-2.83, p = 0.023).
conclusionsRoutine dissection of station 4Sb LNs in LGC offers negligible survival benefit. Furthermore, given that station 1 metastasis is not an independent prognostic factor in LGC, its routine dissection also warrants reconsideration. These findings support a biology-driven refinement of lymphadenectomy guidelines, suggesting that omitting station 4Sb and selectively omitting station 1 in LGC may be oncologically safe. Prospective validation is crucial.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.